Sun Pharma misses Q1 estimates as US generics sales fall 9.7%
Sun Pharma’s Q1 revenue rose 10.5% to ₹15,299 crore and net profit increased 27%, led by 16% India sales growth. US sales fell 9.7% amid generic-drug pricing pressure and competition, while innovative medicines grew 12.8%. Its Organon acquisition is targeted to close in Q4 FY27.
What happened
Sun Pharmaceutical Industries · Sun Pharma missed Q1 Street estimates despite 16% growth in its India business. US generics sales fell 9.7% amid pricing
Key facts
- Q1 consolidated revenue ₹15,299 crore, up 10.5% year-on-year
- Net profit ₹2,895 crore, up 27% year-on-year
- Adjusted net profit ₹3,089 crore, up 3.1%
- EBITDA ₹4,417 crore, up 2.7%; margin 28.9% versus 31.1%
- India sales ₹5,475 crore, up 16% year-on-year
- US sales $427 million, down 9.7% year-on-year
- Innovative medicines sales $351 million, up 12.8% year-on-year
- Organon acquisition enterprise value $11.75 billion
Why this matters
The planned Organon acquisition, targeted for Q4 FY27 close, could strengthen Sun Pharma’s portfolio diversification as its legacy US generics business faces pricing headwinds.
What to watch
- Quarterly US formulation-sales trend and management commentary on price erosion versus volume growth.
- Innovative-medicine growth rate, specialty prescription demand and new-launch contribution.
- India formulation-sales growth, especially chronic, cardiometabolic and dermatology segments.
- USFDA inspection outcomes, approval cadence and any supply disruptions at key manufacturing sites.
- Gross-margin movement, R&D spending and currency effects on US profitability.
- Organon transaction approvals, closing timetable, debt/financing terms and disclosed synergy targets.
- Competitor launches or patent events in Sun Pharma's major US generic products.
- Prioritize higher-margin specialty, complex-generic and innovative-medicine launches in the US rather than defending low-return commodity volumes.
- Use India growth to fund targeted brand-building, chronic-care expansion and field-force investments while protecting consolidated profitability.
- Accelerate manufacturing, filing and supply-chain readiness for differentiated US launches to improve product mix.
- Provide clearer milestones on Organon acquisition financing, regulatory approvals, portfolio fit and post-close synergies ahead of the Q4 FY27 target.
- Review US customer contracts and SKU economics for potential rationalization of persistently loss-making generic products.